

Title	Bacterial microcompartment-directed polyphosphate kinase promotes stable polyphosphate accumulation in E. coli
Authors	Liang, Mingzhi;Frank, Stefanie;Lünsdorf, Heinrich;Warren, Martin J.;Prentice, Michael B.
Publication date	2017-02-10
Original Citation	Liang, M., Frank, S., Lünsdorf, H., Warren, M. J. and Prentice, M. B. (2017) 'Bacterial microcompartment-directed polyphosphate kinase promotes stable polyphosphate accumulation in E. coli', Biotechnology Journal, 12(3), 1600415
Type of publication	Article (peer-reviewed)
Link to publisher's version	10.1002/biot.201600415
Rights	This is the accepted version of the following article: Liang et al (2017), Bacterial microcompartment-directed polyphosphate kinase promotes stable polyphosphate accumulation in E. coli. Biotechnol. J., 12: 1600415 which has been published in final form at http://dx.doi.org/10.1002/biot.201600415 .This article may be used for non-commercial purposes in accordance with the Wiley Self-Archiving Policy [olabout.wiley.com/WileyCDA/Section/id-820227.html]
Download date	2023-05-05 01:36:48
Item downloaded from	http://hdl.handle.net/10468/4211



UCC

University College Cork, Ireland
Coláiste na hOllscoile Corcaigh

Research Article

Title: Bacterial microcompartment-directed polyphosphate kinase promotes stable polyphosphate accumulation in *E. coli*

Mingzhi Liang^{1,2}, Stefanie Frank², Heinrich Lünsdorf³, Martin J Warren^{2*},

Michael B Prentice^{1,4,5*}

¹Department of Microbiology, University College Cork, Cork, Ireland

²School of Biosciences, University of Kent, Canterbury, Kent CT2 7NJ, UK

³Central Facility for Microscopy, Helmholtz Center of Infection Research, Braunschweig, D-38124, Germany

⁴Department of Pathology, University College Cork, Cork, Ireland

⁵APC Microbiome Institute, University College Cork, Cork, Ireland

Correspondence: Professor Michael B Prentice, Department of Microbiology, University College Cork, Cork, Ireland

Email: m.prentice@ucc.ie

Keywords: Metabolic engineering; Synthetic biology; Bacteria; Biopolymers; Microreactors.

Abbreviations: BMC, bacterial microcompartment; enhanced biological phosphorus removal, EBPR; PPK1, polyphosphate kinase; PPX, exopolyphosphatase.

Abstract

Temporary manipulation of bacterial polyphosphate levels by phased environmental stimuli underlies wastewater biological phosphate removal processes. In *E. coli* polyphosphate levels are controlled via polyphosphate kinase (PPK1, synthesizing) and exopolyphosphatases (PPX and GPPA), and are temporarily enhanced by PPK1 overexpression and reduced by PPX overexpression. We hypothesised that partitioning PPK1 from cytoplasmic exopolyphosphatases would increase and stabilise *E. coli* polyphosphate levels. Partitioning was achieved by coexpression of *E. coli* PPK1 fused with a microcompartment-targeting sequence and an artificial operon of *Citrobacter freundii* bacterial microcompartment genes. Encapsulation of targeted PPK1 resulted in stably increased cellular polyphosphate and persistent net phosphate cellular uptake into stationary phase, while temporary polyphosphate increase and phosphate uptake was observed with PPK1 overexpression alone. Targeted PPK1 increased polyphosphate in the microcompartment fraction 8-fold compared with non-targeted PPK1. Co-expression of PPX and non-targeted PPK1 abolished any increase in cellular polyphosphate from PPK1 expression alone. Co-expression of PPX with targeted PPK1 however resulted in elevated polyphosphate levels due to persisting polyphosphate in bacterial microcompartments. Subcellular polymerising enzyme targeting to bacterial microcompartments sequesters metabolic products from competing catabolism by preventing catabolic enzyme access. Specific application of this process to polyphosphate is of potential application for biological phosphate removal.

1. Introduction

Polyphosphate is a molecule thought to be present in all organisms [1] playing a role in cellular metabolic processes, stress response processes, virus replication and cell structure [2]. Bacterial polyphosphate accumulation underlies the enhanced biological phosphorus removal (EBPR) process, which uses microorganisms to remove inorganic phosphate (Pi) from wastewater [3]. Phosphate recovery processes are required to reduce eutrophication, the overgrowth of cyanobacteria and plants in water polluted by excess phosphorus from human activity [4], and because of the unsustainability of current phosphorus resources beyond the next century [5]. In EBPR, cycling of wastewater sludge through aerobic and anaerobic phases of incubation lasting several hours, when continued over a period of weeks selects a bacterial consortium that has a net effect of removing phosphorus from wastewater over the cycle by accumulating it in the sludge. Polyphosphate-accumulating bacteria are key consortium components [6, 7]. Phosphate release from the consortium occurs in the anaerobic phase in parallel with consumption of volatile fatty acids, polyhydroxyalkanoate polymer formation and glycogen utilisation. In the aerobic phase stored polyhydroxyalkanoate is catabolised, glycogen replenished and phosphate taken up to form polyphosphate granules [7]. EBPR is a complex dynamic process - an uncultured bacterium *Candidatus Accumulibacter phosphatis* performs a key role in EBPR polyphosphate accumulation [8], and an established EBPR reactor may fail for unknown reasons [3, 9].

Genetic manipulation of aspects of phosphate binding, uptake and storage by a single model organism such as *E. coli* has been suggested as an alternative or additive approach

1 to biological phosphorus removal [10–13]. One issue with over-expression of a
2 polyphosphate forming enzyme in *E. coli* has been that most of the consequent increase of
3 polyphosphate is temporary, probably because of the existence of competing catabolic
4 enzymes [14, 15] and phosphate release from the cells then occurs as the polyphosphate is
5 broken down.

6
7 In *E. coli* polyphosphate kinase PPK1 (E.C. 2.7.4.1) is the enzyme responsible for
8 assembling inorganic polyphosphate polymers in the bacterial cytoplasm by catalysing the
9 reaction $n\text{ATP} \rightleftharpoons (\text{polyphosphate})_n + n\text{ADP}$ [16, 17]. Although this is a reversible reaction,
10 in *E. coli* this enzyme generally favours synthesis of polyphosphate over breakdown (V_{max}
11 ratio of 4.1) [17] (Fig. 1A). However, the balance between net accumulation and breakdown
12 changes dynamically during culture growth and also in response to external stimuli, in part
13 due to the action of degradative exopolyphosphatases. In this respect *E. coli* contains two
14 such polyphosphatases that release orthophosphate from the termini of long chain
15 polyphosphate: $(\text{polyphosphate})_n \rightarrow (\text{polyphosphate})_{n-1} + \text{P}_i$. The two polyphosphatases
16 are called PPX (E.C. 3.6.1.11, sometimes referred to as PPX1) [18, 19], which is encoded
17 in the same operon as PPK1, and its homologue guanosine pentaphosphate
18 phosphohydrolase (GPPA or PPX2) [17, 20]. GPPA (E.C. 3.6.1.40) also hydrolyses
19 guanosine pentaphosphate (pppGpp) to guanosine tetraphosphate (ppGpp) with phosphate
20 release as part of the control of the stringent response. Both PPX and GPPA are
21 competitively inhibited by pppGpp [21]. Consequently, amino acid starvation in *E. coli*
22 leads to the accumulation of large amounts of polyphosphate due to the high levels of
23 pppGpp produced as part of the stringent response [21]. In *E. coli* *ppk1* and *ppx* are adjacent

1 genes forming an operon and knockout of *ppx* alone has been engineered by combined
2 knockout of *ppk1* and *ppx* with heterologous plasmid expression of *ppk1* [15, 22, 23].
3 Elevation of polyphosphate levels in these cells rapidly declines a few hours after *ppk1*
4 plasmid induction whether *ppx* is active or knocked out [15], showing that PPX is not the
5 sole cause of instability in polyphosphate levels in *E. coli*. We hypothesized that an
6 alternative approach to prevent the access of all other cytoplasmic enzymes, (not just PPX)
7 to polyphosphate formed from recombinant PPK1 would stabilise cellular polyphosphate
8 levels and create a phosphate-retaining phenotype. The mechanism used to achieve this is
9 targeting of PPK1 to a recombinant bacterial microcompartment.

10
11 Bacterial microcompartments (BMCs) are proteinaceous vesicles found in certain bacteria
12 that house specific metabolic pathways encased within a closed polyhedral shell of 100-
13 150 nm diameter. The shells are made of thin protein sheets [24] containing pores less than
14 1 nm in diameter [25] which can be positively or negatively charged. There are two broad
15 groups of BMCs, those associated with the anabolic process of RuBisCO-mediated carbon
16 fixation (carboxysomes) and those associated with catabolic fermentative processes such
17 as 1,2-propanediol utilisation (metabolosomes) [26, 27]. Although BMCs were first seen
18 over fifty years ago in photosynthetic cyanobacteria [28], their presence in the cytoplasm
19 of heterotrophic bacteria was only confirmed in 1998 [29] after they were detected in thin
20 sections of *Salmonella enterica* grown on 1,2-propanediol. In fact, around twenty per cent
21 of bacterial genome sequences contain BMC structural genes [26], in many cases
22 associated with enzymes of unknown function [30].

23

1 A significant proportion of bacteria therefore make a major investment in retaining and
2 expressing large (15+ gene) operons encoding these structures and associated enzymes. It
3 is believed the structures help mediate metabolic efficiency by selective limitation of the
4 shell pores on the passage of substrates [31], by metabolite channelling, or other
5 mechanisms achieving retention of reaction intermediates within the structure [32, 33].
6 *Salmonella enterica* Serovar Typhimurium accrues a competitive metabolic advantage by
7 BMC-mediated respiration of ethanolamine in a mouse colitis model [34].
8 Enterohaemorrhagic *E. coli* obtains a similar competitive advantage from BMC-mediated
9 ethanolamine fermentation in bovine intestinal fluid [35], favouring persistent intestinal
10 carriage.

11
12 Recombinant BMCs using genes from *Citrobacter freundii* can be expressed
13 heterologously in *E. coli* [36], both with and without [37] the associated interior enzymes.
14 Peptide sequences enabling enzyme localisation to the BMC interior have been identified
15 [37] [38]. For instance, the first 18 amino acids of PduP, P18, or the first 18 or 60 amino
16 acids of PduD (D18 or D60) can be used as fusions to direct “foreign” proteins into the
17 BMC [39]. Compartmentalisation of the cellular interior is a functionally transforming
18 process often thought of as characteristic of eukaryotes [40], but specific localisation of
19 any enzyme to a re-engineered BMC in bacteria could increase metabolic flexibility of the
20 bacterial host enabling novel phenotypes [41]. Nanotechnological applications of other
21 biological compartment systems have included the use of viral capsids for DNA delivery
22 [42], lumazine synthase enclosure of HIV protease [43], and the engineering of novel
23 metabolites. We hypothesized that directing PPK to a BMC would enhance polyphosphate

formation within a cellular compartment and that segregation from the known degradative polyphosphatases and other cytoplasmic enzymes should stabilise accumulation of polyphosphate (Fig.1).

2. Materials and Methods

Strains, plasmids and culture conditions

E. coli was grown in LB or MOPS medium [44] with either 0.5 mM or 1.0 mM K₂HPO₄ as indicated. Expression of pET cloned genes was induced by IPTG in *E. coli* BL21 (DE3) and *E. coli* BL21 Tuner (DE3) (Novagen). Strains and plasmids are listed in Table 1 and oligonucleotides in Supplementary Data Table S1. Incubation for phosphate uptake experiments was at 37 °C, otherwise pDuet inductions were incubated at 18 °C.

Molecular techniques

Plasmid cloning was carried out in *E. coli* JM109 or *E. coli* TOP10 (Invitrogen) with subsequent transfer to *E. coli* BL21 (DE3) and *E. coli* BL21 Tuner (DE3) for expression using standard transformation techniques [45]. For PCR experiments standard protocols were applied using an MJ Research PTC-200 Thermal Cycler for reaction cycles. Genomic DNA was extracted from *E. coli* JM109 using a Wizard® Genomic DNA Purification Kit (Promega). Plasmid constructs were sequenced commercially (GATC Biotech).

Targeting of PPK1

The strategy used is summarised in Supplementary Data Fig.S1. The *ppk1* gene coding for polyphosphate kinase (PPK1) was PCR-amplified with a proofreading DNA polymerase

(Bioline High Velocity Polymerase, Bioline UK, London), using genomic DNA from *E. coli* JM109 as template, using the forward primer ppk1-F and a reverse primer ppk1-R (Table S1). The PCR product was digested with *Sac* I and *Hind* III (Fermentas) followed by ligation to pET23b-GFP-pduP18 digested with *Sac* I and *Hind* III. The gene encoding the GFP was thus replaced by *ppk* with retention of the *pdu* localization sequence. The ligation product was transformed into *E. coli* Top 10 electrocompetent cells (Invitrogen) by electroporation. The new vector, named pML001 (pET23bpduP18-*ppk1*), was extracted and the *ppk1* insert was sequenced (GATC-Biotech) to confirm no mutation had occurred. Two constructs, pML001 and pLysSpduABJKNU (pSF37), expressing an empty *pdu* BMC [37]), were co-transformed into *E. coli* BL21 (DE3) by heat shock.

Co-localisation of PPK1 and Microcompartments

Peptide fingerprinting of microcompartment cellular fraction

Recombinant BMCs were extracted from *E. coli* by a modification of a published method [46]. A single colony pick was grown in 200 ml of LB to an OD of 0.4 followed by induction with 0.4 mM IPTG. Cells at OD1.0-1.2 were harvested and washed twice with 40 ml of buffer A (50 mM Tris-HCl (pH 8.0), 500 mM KCl, 12.5 mM MgCl₂, 1.5% 1,2-PD). Cells (1 g wet weight) were resuspended in a mixture of 10 ml of buffer A and 15 ml of BPER-II supplemented with 5mM mercaptoethanol, Complete Protease Inhibitor Cocktail (Roche) at the manufacturer's recommended working dilution, 25 mg of lysozyme, and 2 mg of DNase I. The suspension was incubated for 30 min on a shaking incubator at room temperature and on ice for 5 min. After initial removal of cell debris by

centrifugation at 12,000 *g* for 5 min at 4°C repeated twice, the BMC fraction was precipitated by spinning at 20,000 *g* for 20 min at 4°C. The pellet was washed once with a mixture of 4 ml of buffer A and 6 ml of BPER-II and resuspended in 0.5 ml of buffer B (50mM Tris-HCl pH 8.0, 50 mM KCl, 5 mM MgCl₂, 1% 1,2-PD) containing Complete Protease Inhibitor Cocktail (Roche) at the manufacturer's recommended working dilution. Remaining cell debris was removed by centrifugation for 1 min at 12,000 *g* 4°C repeated three times. Aliquots (50 μ g) of extracted protein were separated by SDS-PAGE using a 15% polyacrylamide gel under denaturing conditions in a MiniProtean apparatus (Bio-Rad) and stained with Coomassie Brilliant Blue R250 (Fig.1B). Peptide fingerprinting carried out as previously described [47]. In microcompartment extraction for ATP regeneration assays (Fig. 1C,D) and whole cell polyphosphate assays (Fig 2) CellLytic B (Sigma-Aldrich) was initially substituted for BPER-II because of published efficacy of this reagent for polyphosphate extraction [48]. In later microcompartment extractions (Fig. 3) comparisons of BPER-II extractions and CellLytic B extractions had shown little difference in measured polyphosphate levels and BPER-II was used. Micrococcal nuclease 2 mg (Sigma-Aldrich) prepared with calcium buffer was substituted for DNase 1 for all microcompartment extractions where polyphosphate was assayed because of the potential adverse effect of Mg²⁺ containing buffers on polyphosphate [49].

ATP regeneration assay

A combination of two previously described PPK1 assay methods [48, 50] using luciferase to detect ATP produced from polyphosphate by PPK1 was used as a biochemical screen for the presence of PPK1 and polyphosphate in microcompartment fractions. Briefly, to assay relative PPK1 content 20 μ L of BMC extract was added to a 100 μ L reaction mixture

1 containing: ultrapure ADP (ATP-free, Cell Technology Inc, Ca), 30 mM MgCl₂, 1% (w/v)
2 Polyphosphate (Sigma), 50 mM Tris-HCl (pH 7.8). The reaction mixture was diluted 1:100
3 in 100 mM Tris-HCl (pH 8.0)–4 mM EDTA, of which 0.1 mL was added to 0.1 mL of
4 luciferase reaction mixture from ATP Bioluminescence Assay Kit CLS II (Roche).
5 Luminescence was measured by using a luminometer (Luminoskan, Thermo Labsystems).
6 A standard curve for ATP by dilution in 100 mM Tris-HCl (pH 8.0) containing 4 mM
7 EDTA was used. To assay relative polyphosphate content, the same reaction omitting
8 added polyphosphate was performed (Figure 1C).

9

10 **Co-expression of targeted and untargeted PPK1 and PPX**

11 The pCOLADuet-1 coexpression vector (Novagen) system encoding two multiple cloning
12 sites (MCS) each preceded by a T7 promoter, *lac* operator, and ribosome binding site was
13 used to express targeted and untargeted *E. coli* PPK1 and PPX (*ppx* amplified from *E. coli*
14 JM109) in combination (pYY005, pYY007, pYY008) and alone (pYY002, pYY010) (see
15 Table 1).

16 Polyphosphate concentration presented in Fig. 3 was determined following lysis of pelleted
17 cells from 10 ml of cultures described above. A metachromatic assay was employed using
18 the 530/630nm absorbance ratio of 10 µL of lysate added to 1 mL of toluidine dye solution
19 (6 mg/L toluidine blue in 40 mM acetic acid) as described [51]. In later experiments (Fig.
20 4) polyphosphate was determined by a higher-yielding method using 4'-6-diamidino-2-
21 phenylindole (DAPI) as described [52] on whole cells or microcompartment cell fractions
22 obtained with BPER-II extraction. Briefly, cells were harvested by centrifuging at 5000g
23 for 10 min at 4° C. After washing in 50mM HEPES buffer (pH7.5) the cell pellet or

1 microcompartment fraction was frozen at -20° C followed by defrosting at room
2 temperature. Cell pellets/microcompartment fractions were resuspended in HEPES buffer
3 at an appropriate dilution to ensure that the cellular polyP concentration was in the linear
4 range of the DAPI assay (0-6 μ g polyP/ml). Total assay volume was 300 μ l which included
5 100 μ L of polyP containing samples and 200 μ L of DAPI assay buffer containing 150 mM
6 KCl, 20 mM HEPES-KOH (pH 7.0) and 10 μ M DAPI solution. After a 10 min incubation
7 at room temperature DAPI fluorescence was measured with a platereader equipped with
8 excitation and emission filters of 420 nm and 550 nm respectively.

9
10 A polyphosphate standard curve was prepared using sodium phosphate glass Type 45
11 (S4379 Aldrich) and sodium hexametaphosphate (SX0583). Protein concentration of cell
12 extracts was measured using a 10 μ L sample, with Coomassie Plus Protein Assay Reagent
13 (Pierce) with bovine serum albumin as the standard resuspended in the same buffer as the
14 sample.

15
16 **Phosphate uptake** was determined as follows (Fig. 2A). Bacteria was grown to OD₆₀₀ 0.4-
17 0.6 in Luria broth and then induced by 0.5 mM of IPTG for 1 hr before transfer to pH 5.5
18 MOPS medium [44] containing 0.01 mM iron and 0.5 mM potassium phosphate, at an
19 OD₆₀₀ of 0.2. Incubation was continued at 37°C with intermittent sampling of 0.2 mL up
20 to 48 hrs. Samples were centrifuged and supernatant used for phosphate assay, and the
21 pellet used for polyphosphate and protein assays. Phosphate was assayed using a
22 molybdovanadate colorimetric method [53]. 0.2 mL of molybdovanadate solution
23 (Reagecon, cat no: 1056700) was added to 5 mL of culture supernatant, mixed and

1 incubated at room temperature for 5 min. Optical density of 1 mL at 430 nm was measured
2 against a blank of 4% molybdovanadate in distilled water and a calibration curve of
3 potassium phosphate in MOPS.

5 **Light Microscopy**

6 Polyphosphate granules were visualised in fixed films (Fig. 4) by Neisser's stain using
7 Chrysoidin counterstain [54].

9 **Electron Microscopy**

10 *E. coli* BL21(DE3) cells containing targeted/untargeted PPK1 and pLySsPduABJKNU (for
11 expressing empty microcompartments) were grown in 50 mL of LB broth containing 100
12 mg/litre ampicillin and 32 mg/L chloramphenicol with shaking at 37 °C. Upon reaching an
13 OD₆₀₀ of 0.5, protein production was induced with 0.5 mM isopropyl-D-thiogalactoside,
14 and the cultures were incubated by shaking overnight at 18 °C. Harvested cells were
15 resuspended in 2 mL of fixative consisting of 2.5% glutaraldehyde in 100 mM sodium
16 cacodylate (CAB) buffer (pH 7.2). The cells were pelleted and washed twice with CAB to
17 remove traces of the fixing solution. Cells were then stained for 1 hr in 1% osmium
18 tetroxide (w/v) and washed with CAB before dehydration. Dehydration was carried out by
19 placing the samples into an ethanol gradient: 50%, 70%, 90% once for 10 minutes, and
20 100% dried ethanol three times for 15 minutes. Samples were rinsed twice for 15 minutes
21 in propylene oxide and then incubated in 50/50 propylene oxide/Agar LV resin for 30
22 minutes. Samples were incubated 2 x 2 hr in fresh Agar LV resin before embedding in
23 Beem capsules by centrifugation at 11,000 rpm for 5 minutes followed by incubation at 60

1 °C overnight to polymerize. Specimens were thin sectioned with a diamond knife on an
2 RMC MT-6000-XL ultramicrotome, collected on 400 mesh copper grids, and post-stained
3 with 4.5% uranyl acetate for 45 min at RT and lead citrate for 7 min at RT. Sections were
4 then observed and photographed with a JEOL-1230 transmission electron microscope at
5 an accelerating voltage of 80 kV.

6 7 **Electron microscopy for parallel electron energy loss spectroscopy (PEELS) and** 8 **element mapping by electron spectroscopic imaging (ESI)**

9 Unstained cells were fixed in 3% (v/v) glutaraldehyde – 10 mM Hepes, pH 7.3 (Sigma),
10 dehydrated in an acetone-series and embedded in epoxy resin (Spurr, hard mixture; [55]),
11 as described [56]. For elemental analysis 30 - 40 nm ultrathin sections (otherwise 90 nm
12 for general ultrastructure) were sectioned with a Reichelt-Jung ultramicrotome (Leica,
13 Vienna, Austria), equipped with a diamond knife and were picked up with 300 mesh Cu-
14 grids. Electron micrographs were recorded in the elastic brightfield mode (slit width: 10
15 eV) with an EF-TEM (operated in general at 120 kV acceleration voltage), equipped with
16 an in-column Omega-type energy filter (LIBRA120 plus, Zeiss, Oberkochen Germany), in
17 a magnification range from x 4000 to x 32000 with a bottom-mount cooled 2048 x 2048
18 CCD camera (sharp:eye; Tröndle, Moorenweis, Germany).

19 20 **Parallel electron energy loss spectroscopy (PEELS)**

21 Spot-PEELS were recorded within electron dense cytoplasmic inclusion bodies. Spot-size
22 was set to 16 nm and the objective aperture was 60 µm (spectrum magnification: x100;
23 energy range: 67 – 290 eV; recording time: 10 s ; emission current: 1 µA) and the spectrum

energy resolution was about 1.6 eV at zero-loss (FWHM). Recorded PEELS data were corrected for background, applying the 'potence' underground function of the EsiVision Pro Software (EsiVision Pro, Vers. 3.2; SIS – Soft Imaging Systems, Munster, Germany) and were 'medium'-filtered (settings: 1.5 eV width).

Element mapping by electron spectroscopic imaging (ESI)

Phosphorus mapping was performed as previously described [56] with unstained 35 nm ultrathin sections. According to the '3-window method' energy-windows were set to a dedicated energy loss for the P-L23 edge, as it was given by the corresponding first intensity maximum from the spot-PEELS, i.e. 138 eV (W1: 125 eV; W2: 115 eV). The energy selective slit was set to 6 eV width, and images were recorded with an illumination aperture of 0.63 mrad, an emission current of 1 μ A, a 60 μ m objective aperture, and a nominal magnification of x 6300. Background subtraction for calculating the phosphorus element map was performed by the 'multiwindow exponential difference' method.

3. Results

BMC localisation of PPK1

The localisation of PPK1 to a recombinant BMC was achieved by engineering the fusion of the P18 targeting peptide to the N-terminus of the enzyme. The recombinant BMC with the associated P18-PPK1 was isolated after lysis of the cells using a protein extraction reagent followed by differential salt precipitation and centrifugation. Analysis of the purified BMC fraction by SDS-PAGE revealed the presence of P18-PPK1 together with the BMC-associated shell proteins (Fig. 1B).

A functional assay designed to maximise PPK1's ATP breakdown function was employed to determine the activity of PPK1 when it was directed to the BMC. In comparison to BMC extracts from cells producing only empty BMCs or empty BMCs and non-targeted PPK, the purified BMC cell fractions from the cells co-producing BMCs and P18-PPK1 generated over twenty-fold more ATP per mg of protein from added polyphosphate (Fig.1C). There was little activity in the equivalent protein fraction that had been prepared from cells producing only P18-PPK1 (i.e. P18-PPK1 produced in the absence of BMCs). This showed that polyphosphate kinase activity had been transferred to the microcompartments by enzyme targeting.

The same ATP regeneration assay was run again but this time in the absence of any added exogenous polyphosphate (Fig.1D). Any ATP generated in this assay would therefore reflect the amount of endogenous polyphosphate within the fraction. The BMC fraction from the cells that co-produced both the BMCs and P18-PPK1 generated more than twice as much ATP as control BMC fractions from cells expressing empty BMCs or BMCs with non-targeted PPK1 (Fig. 1D). This result indicates that the BMC fraction from cells co-expressing targeted PPK1 had increased levels of polyphosphate, compatible with localisation of PPK1 to the microcompartment and formation of polyphosphate in situ.

PPK1 targeting effect on polyphosphate content and phosphate uptake,

The effect of PPK1 overexpression on cellular polyphosphate was both qualitative and quantitative, and targeted PPK1 with co-expressed BMCs gave a distinct phenotype. DAPI

negative staining of polyphosphate extracts, size-separated on a PAGE gel (Supplementary Data Figure S2), showed that the polyphosphate detected in strains over-expressing either *p18ppk1* alone or *p18ppk1* and *pduABJKNU* exceeded the length of the sodium phosphate glass Type 45 polyphosphate control. This indicates that long chain polyphosphate is present in these strains. No qualitative difference in chain length was detected between these two clones but long chain polyphosphate in the *E. coli* strain over expressing *p18ppk1* and recombinant BMCs persisted to a later phase of growth (Fig. S2) than in cells expressing *p18ppk1* alone. No long chain polyphosphate was detected in the *E. coli* control.

A simultaneous assay of the cellular polyphosphate and phosphate content of the culture supernatant from the cultures used in the polyphosphate chain length assay was also undertaken. Here, increased phosphate uptake from culture medium was observed in comparison to the host *E. coli* control (Fig. 2A) by both the *p18ppk1*-expressing strain and the strain expressing both *p18ppk1* and *pduABJKNU*. A maximal uptake of approximately 0.25 mM at 20 hours was observed for both constructs. However, the *p18ppk1*-expressing strain returned a third of this phosphate to the supernatant after 48 hours, while the strain expressing both *p18ppk1* and *pduABJKNU* returned less than 9% of phosphate taken by 48 hours. Correspondingly, the cell associated polyphosphate levels of the *p18ppk1* clone were maximal at 20 hours and declined thereafter, while the *p18ppk1* and *pduABJKNU* expressing strain retained approximately the same level of cell associated polyphosphate at 48 hours as at 20 hours.

BMC protects endogenous polyphosphate from exogenous polyphosphatases

1 The induction of non-targeted PPK1 from the pDuet vector increased whole cell
2 polyphosphate levels 5-fold in comparison to control cells containing the BMC shell
3 protein operon and the pDuet vector with no enzyme insert (the enzyme-free control, Fig.
4 3). It did not increase the polyphosphate content of co-expressed recombinant
5 microcompartments when compared to the enzyme-free control. However, P18-PPK1,
6 when co-produced with the BMCs, increased polyphosphate levels in the BMC fraction 8-
7 fold in comparison to the enzyme-free control, while giving a similar overall 5-fold
8 increase in whole cell polyphosphate to that seen with expression of non-targeted PPK1.

9
10 Co-expression of non-targeted polyphosphatase PPX with non-targeted PPK1 reduced
11 whole cell polyphosphate levels by 50% compared with non-targeted PPK1 expression
12 alone, with little effect on polyphosphate levels in the microcompartment fraction. Co-
13 expression of non-targeted PPX and BMC-targeted P18-PPK1 reduced whole cell
14 polyphosphate levels by 22% and BMC-associated polyphosphate by 18% when compared
15 with microcompartment targeted PPK1 alone. BMC-associated polyphosphate was still at
16 least 2.5 times greater than in cells co-expressing non-targeted PPK1 in the presence or
17 absence of non-targeted PPX. Co-expression of BMC targeted P18-PPK1 with PPX
18 targeted to the microcompartment using a different tag (D60) reduced the BMC-associated
19 polyphosphate content by 50% in comparison to the BMC-targeted P18-PPK1 alone, while
20 reducing whole cell polyphosphate by 22%. These data suggest that the BMC-targeting of
21 PPK1 results in the synthesis of polyphosphate that is located primarily within the BMC
22 fraction of the cell and is relatively inaccessible to cytoplasmic co-expressed PPX, but
23 more accessible to BMC-targeted PPX.

1

2 **Microscopy**

3 Blue-black granules were apparent with Neisser's stain in a proportion of all cells
4 overexpressing P18-PPK1, but not the *E. coli* BL21 insert-free control or without any
5 targeted enzyme (Fig. 4). These appearances are consistent with the accumulation of
6 intracellular polyphosphate in *E. coli* cells with increased PPK1 activity. All cells
7 overexpressing P18-PPK1 showed a heterogeneous granule phenotype, with a proportion
8 of non-toluidine blue staining cells in all fields.

9

10 *E. coli* expressing the recombinant microcompartment and P18-PPK1 retained the
11 polyphosphate staining at 44 hours (Fig. 4) whereas cells expressing P18-PPK1 without
12 the recombinant microcompartment showed reduced staining after 40 hours (Fig. 3).

13 All *E.coli* expressing the recombinant microcompartment had a proportion of cells which
14 were greatly elongated. All *E.coli* forming multiple polyphosphate granules tended to be
15 larger than the non-granulated cells, presumably because of distension by the granules.
16 However, the largest cells were seen with the combination of recombinant
17 microcompartment and P18-PPK1.

18

19 **Electron-loss spectroscopic analysis by Energy-filtered Transmission Electron** 20 **Microscopy (EFTEM).**

21

22 Increased phosphorus deposition was detected in all cells expressing recombinant *E.coli*
23 PPK1 (Fig. 5C,D,E,F), verified from PEELS measurement (see below), compared with

control *E. coli* strains with no recombinant gene expression (Fig. 5A) or expressing microcompartment genes (Fig. 5B). In cells expressing PPK1 alone, most phosphate signal was represented by particles <5 nm, but some large homogeneous masses > 200 nm with plane edges were visible (Fig. 5C) in a few cells. In cells expressing targeted PPK1 and a recombinant microcompartment operon, in addition to signals from particles <5 nm, multiple phosphate signals from particles 50-100 nm were present (Fig. 5D,E,F) and in some cases large circular masses/crescents > 300 nm were present (Fig. 5D,F). These large masses were not homogeneous and appeared composed of small particles and the cells containing them were enlarged. These images appeared similar to light microscopy observations (Fig. 4D,H,L).

Parallel electron energy loss spectroscopy (PEELS)

Spot-PEELS recorded from dark inclusions apparent as electron dense regions about 100 nm in diameter (Fig 5G), confirmed they contained phosphate, verified from the characteristic ELNES-fingerprint (Energy-Loss Near-Edge Structure) of reference spectra that were recorded from sodium polyphosphate (Fig. 5G). The largest polyphosphate inclusion in figure 5E, shown in yellow, is magnified in the inset of the spot-PEELS (Fig. 5G); here the 16 nm beam spot and its position are indicated (white circle).

4. Discussion

Polyphosphate accumulation is the basis of the enhanced biological phosphorus removal (EBPR) process, which uses microorganisms to remove inorganic phosphate (Pi) from wastewater. Accumulation occurs in aerobic conditions as intracellular polyphosphate [8, 12] is released as Pi in anaerobic conditions [57] and supplied with organic carbon or heated [12]. The best characterized enzyme responsible for polyphosphate synthesis (PPK1), originally found in *E. coli* [58], can only be detected by bioinformatics in the genome sequences of a minority of bacterial genera [59]. The enzyme responsible for polyphosphate synthesis in most bacteria therefore remains to be identified [59].

In *E. coli*, polyphosphate accumulation in wild-type strains occurs with amino acid starvation or in the stationary phase [21, 50, 60]. Large amounts of polyphosphate accumulate only if the copy number of *ppk* is increased, or a heterologous *ppk* gene is supplied, or *phoU* is mutated [61]. Even in *E. coli* strains overexpressing *ppk*, initial accumulation of polyphosphate is known to be partially or completely reversed as the cells reach stationary phase [14, 15]. Because this also occurs in *E. coli* overexpressing *ppk* with no chromosomal functioning *ppx* gene it has been suggested to be due to either product-induced reversal of the PPK-catalysed reaction, or the activity of another phosphatase enzyme present in the cytoplasm [15]. We observed a similar reversal of polyphosphate accumulation in our overexpressing *ppk* clone, accompanied by increasing Pi in the culture supernatant (Fig. 2). This did not occur when the *ppk* gene was engineered to encode an N-terminal BMC localisation sequence and was expressed in trans with an operon encoding for an empty BMC.

Cells co-producing P18-PPK1 and the empty BMC had a different phosphorus distribution by EFTEM (Fig 5D,E,F) to those expressing PPK1 alone (Fig. 5C), containing single or agglomerated particles in the BMC size range. BMC extractions show the presence of metabolically active PPK1 (Fig.1C,D) and polyphosphate in the BMC fraction (Fig.1D, Fig.3) when PPK1 is microcompartment-targeted in this way. Our results suggest that targeting of PPK1 to a bacterial microcompartment still allows access of the small molecule substrate ATP to the enzyme (Figure 1A), but effectively stabilises the large polymer polyphosphate product (Fig. 2B,3).

We hypothesized that this stabilisation results from reduced access of PPX, GPPA or other cytoplasmic phosphatases to the polyphosphate produced by BMC-targeted PPK1. To confirm this we carried out co-expression experiments of PPK1 with PPX (Fig. 3). Co-production of PPX with PPK1 resulted in lower cellular polyphosphate levels than expression of *ppk1* alone (Fig. 3), as has been previously reported [62]. This reduction in total cellular polyphosphate was partially prevented by BMC-association of PPK1, due to increased levels of polyphosphate in the BMC fraction. BMC-targeting of PPK1 therefore results in the synthesis of polyphosphate that is located primarily in the BMC fraction of the cell. Polyphosphate in the BMC fraction is inaccessible to cytoplasmic co-expressed PPX. Adding BMC targeting to PPX (D60-PPX) co-expressed with targeted PPK1 (P18-PPK1) partially reverses the increase in polyphosphate levels in the BMC fraction conferred by targeted PPK1, presumably by increasing access of the PPX to polyphosphate in the BMC fraction. This suggests that the mechanism of stabilisation of

polyphosphate conferred by BMC targeting of PPK1 involves reduced access by cytoplasmic phosphatases.

Other examples of such macromolecular association of enzymes exist. A variant of lumazine synthase was recently employed to encapsidate HIV protease within an *E. coli* host [43] facilitating recombinant synthesis of this potentially toxic enzyme by separating it from the remaining cytoplasm. Lumazine synthase compartments are genetically unrelated to BMCs involved in catabolic metabolism, and form pentameric components form smaller 30-40 nm icosahedral structures that more closely resemble viral capsids [63]. The enzyme is bound to part of the shell molecule forming the inner surface by an electrostatic mechanism [43, 64], (N-terminal fusion displays it on the outside [65]). Enzymically active inclusion bodies can be formed within bacterial cells by C-terminal attachment of short self-assembling peptide sequences [66], or N-terminal fusion with a self aggregating protein [67] but these enzymes are not enclosed within a structure accessed via pores. Subcellular localisation of enzymes catalysing successive reactions in a metabolic pathway to peroxisomes in fungi [68] or BMCs [39] can promote product formation.

Our results demonstrate that P18-PPK1 is targeted to a recombinant BMC. The observation that polyphosphate accumulates within the BMC suggests that targeted PPK1 is internalised within the structure and remains functional, generating polymeric product. ATP must be able to enter the recombinant BMC to allow it to act as one of the substrates for the P18-PPK1 enzyme (Fig. 1A). However, this is not surprising as the native Pdu

BMC must allow ATP access as it is required by PduO (located within the microcompartment) for the regeneration of the coenzyme form of cobalamin needed by the diol dehydratase complex [69]. The association of PPK1 with the BMC however leads to sequestration of the enzyme's metabolic product, presumably because its size does not allow it to leave the BMC by the same route by which the enzyme substrate ATP arrived. Protection of the polyphosphate product from catabolism from cytosolic enzymes is therefore achieved, illustrating a general mechanism by which BMC can be used to re-engineer cellular metabolism. The specific polymer generated, polyphosphate, is an important intermediary in the enhanced biological phosphate removal (EBPR) process employing environmental bacteria to remove phosphate from wastewater [3, 12] and has industrial applications [70]. EBPR requires prolonged cycles of aerobic and aerobic incubation to operate. The ability to stabilise polyphosphate produced in a single growth phase so that phosphate is not returned to the cell exterior could lead to a streamlined process with a single phase of incubation. This would require transfer of the recombinant microcompartment and targeted enzyme from *E. coli* to a more environmentally robust organism.

5. References

1. Kulaev I, Kulakovskaya T. POLYPHOSPHATE AND PHOSPHATE PUMP. Annual Review of Microbiology. 2000;54:709-734.
2. Brown MRW, Kornberg A. The long and short of it - polyphosphate, PPK and bacterial survival. Trends in Biochemical Sciences. 2008;33:284-290.
3. Gebremariam SY, Beutell MW, Christian D. Research Advances and Challenges in the Microbiology of Enhanced Biological Phosphorus Removal A Critical Review. Water Environment Research. 2011;83:195-219.
4. Smith VH, Schindler DW. Eutrophication science: where do we go from here. Trends in Ecology & Evolution. 2009;24:201-207.
5. Sverdrup HU, Ragnarsdottir KV. Challenging the planetary boundaries II:

- 1 Assessing the sustainable global population and phosphate supply, using a systems
2 dynamics assessment model. *Applied Geochemistry*. 2011;26:S307-S310.
- 3 6. Fuhs GW, Chen M. Microbiological basis of phosphate removal in the activated
4 sludge process for the treatment of wastewater. *Microbial Ecology*. 1975;2:119-
5 138.
- 6 7. McMahon KD, Read EK. Microbial contributions to phosphorus cycling in
7 eutrophic lakes and wastewater. *Annual review of microbiology*. 2013;67:199-219.
- 8 8. Garcia Martin H, Ivanova N, Kunin V, Warnecke F, Barry KW, McHardy AC,
9 Yeates C, He S, Salamov AA, Szeto E, Dalin E, Putnam NH, Shapiro HJ,
10 Pangilinan JL, Rigoutsos I, Kyrpides NC, Blackall LL, McMahon KD, Hugenholtz
11 P. Metagenomic analysis of two enhanced biological phosphorus removal (EBPR)
12 sludge communities. *Nat Biotech*. 2006;24:1263-1269.
- 13 9. Okunuki S, Kawaharasaki M, Tanaka H, Kanagawa T. Changes in phosphorus
14 removing performance and bacterial community structure in an enhanced biological
15 phosphorus removal reactor. *Water Res*. 2004;38:2432-2438.
- 16 10. Keasling JD, Dien SJV, Pramanik J. Engineering polyphosphate metabolism in
17 *Escherichia coli*: Implications for bioremediation of inorganic
18 contaminants. *Biotechnology and Bioengineering*. 1998;58:231-239.
- 19 11. Li Q, Yu Z, Shao X, He J, Li L. Improved phosphate biosorption by bacterial
20 surface display of phosphate-binding protein utilizing ice nucleation protein. *FEMS*
21 *Microbiol Lett*. 2009;299:44-52.
- 22 12. Hirota R, Kuroda A, Kato J, Ohtake H. Bacterial phosphate metabolism and its
23 application to phosphorus recovery and industrial bioprocesses. *Journal of*
24 *Bioscience and Bioengineering*. 2010;109:423-432.
- 25 13. Choi SS, Lee HM, Ha JH, Kang DG, Kim CS, Seo JH, Cha HJ. Biological Removal
26 of Phosphate at Low Concentrations Using Recombinant *Escherichia coli*
27 Expressing Phosphate-Binding Protein in Periplasmic Space. *Applied biochemistry*
28 *and biotechnology*. 2013;171:1170-1177.
- 29 14. Kato J, Yamada K, Muramatsu A, Hardoyo, Ohtake H. Genetic improvement of
30 *Escherichia coli* for enhanced biological removal of phosphate from wastewater.
31 *Applied and Environmental Microbiology*. 1993;59:3744-3749.
- 32 15. Jones KL, Kim S-W, Keasling JD. Low-Copy Plasmids can Perform as Well as or
33 Better Than High-Copy Plasmids for Metabolic Engineering of Bacteria. *Metabolic*
34 *Engineering*. 2000;2:328-338.
- 35 16. Akiyama M, Crooke E, Kornberg A. The polyphosphate kinase gene of *Escherichia*
36 *coli*. Isolation and sequence of the *ppk* gene and membrane location of the protein. *J*
37 *Biol Chem*. 1992;267:22556-22561.
- 38 17. Rao NN, Gomez-Garcia MR, Kornberg A. Inorganic Polyphosphate: Essential for
39 Growth and Survival. *Annual Review of Biochemistry*. 2009;78:605-647.
- 40 18. Akiyama M, Crooke E, Kornberg A. An exopolyphosphatase of *Escherichia coli*.
41 The enzyme and its *ppx* gene in a polyphosphate operon. *Journal of Biological*
42 *Chemistry*. 1993;268:633-639.
- 43 19. Alvarado J, Ghosh A, Janovitz T, Jauregui A, Hasson MS, Sanders DA. Origin of
44 exopolyphosphatase processivity: Fusion of an ASKHA phosphotransferase and a
45 cyclic nucleotide phosphodiesterase homolog. *Structure*. 2006;14:1263-1272.
- 46 20. Keasling JD, Bertsch L, Kornberg A. Guanosine pentaphosphate phosphohydrolase

- of *Escherichia coli* is a long-chain exopolyphosphatase. Proceedings of the National Academy of Sciences of the United States of America. 1993;90:7029-7033.
21. Kuroda A, Murphy H, Cashel M, Kornberg A. Guanosine tetra- and pentaphosphate promote accumulation of inorganic polyphosphate in *Escherichia coli*. J Biol Chem. 1997;272:21240-3.
22. Crooke E, Akiyama M, Rao NN, Kornberg A. Genetically altered levels of inorganic polyphosphate in *Escherichia coli*. J Biol Chem. 1994;269:6290-6295.
23. Grillo-Puertas M, Villegas JM, Rintoul MR, Rapisarda VA. Polyphosphate degradation in stationary phase triggers biofilm formation via LuxS quorum sensing system in *Escherichia coli*. PLoS One. 2012;7:e50368.
24. Kerfeld CA, Sawaya MR, Tanaka S, Nguyen CV, Phillips M, Beeby M, Yeates TO. Protein structures forming the shell of primitive bacterial organelles. Science. 2005;309:936-938.
25. Pang A, Liang M, Prentice MB, Pickersgill RW. Substrate channels revealed in the trimeric *Lactobacillus reuteri* bacterial microcompartment shell protein PduB. Acta crystallographica Section D, Biological crystallography. 2012;68:1642-1652.
26. Kerfeld CA, Heinhorst S, Cannon GC. Bacterial Microcompartments. Annual Review of Microbiology. 2010;64:391-408.
27. Jorda J, Lopez D, Wheatley NM, Yeates TO. Using comparative genomics to uncover new kinds of protein-based metabolic organelles in bacteria. Protein Science. 2013;22:179-195.
28. Niklowitz W, Drews G. Beiträge zur Cytologie der Blaualgen [Cytology of blue algae. IV. Comparative electron microscopic studies on the substructure of some Hormogonales]. Archives of Microbiology. 1956;24:134-146.
29. Shively JM, Bradburne CE, Aldrich HC, Bobik TA, Mehlman JL, Jin S, Baker SH. Sequence homologs of the carboxysomal polypeptide CsoS1 of the thiobacilli are present in cyanobacteria and enteric bacteria that form carboxysomes - polyhedral bodies. Canadian Journal of Botany-Revue Canadienne De Botanique. 1998;76:906-916.
30. Axen SD, Erbilgin O, Kerfeld CA. A taxonomy of bacterial microcompartment loci constructed by a novel scoring method. PLoS Comput Biol. 2014;10:e1003898.
31. Dou Z, Heinhorst S, Williams EB, Murin CD, Shively JM, Cannon GC. CO₂ Fixation Kinetics of *Halothiobacillus neapolitanus* Mutant Carboxysomes Lacking Carbonic Anhydrase Suggest the Shell Acts as a Diffusional Barrier for CO₂. J Biol Chem. 2008;283:10377-10384.
32. Sampson EM, Bobik TA. Microcompartments for B₁₂-dependent 1,2-propanediol degradation provide protection from DNA and cellular damage by a reactive metabolic intermediate. J Bacteriol. 2008;190:2966-2971.
33. Penrod JT, Roth JR. Conserving a Volatile Metabolite: a Role for Carboxysome-Like Organelles in *Salmonella enterica*. J Bacteriol. 2006;188:2865-2874.
34. Thiennimitr P, Winter SE, Winter MG, Xavier MN, Tolstikov V, Huseby DL, Sterzenbach T, Tsolis RM, Roth JR, Bäuml AJ. Intestinal inflammation allows *Salmonella* to use ethanolamine to compete with the microbiota. Proceedings of the National Academy of Sciences. 2011;108:17480-17485.
35. Bertin Y, Girardeau JP, Chaucheyras-Durand F, Lyan B, Pujos-Guillot E, Harel J, Martin C. Enterohaemorrhagic *Escherichia coli* gains a competitive advantage by

- using ethanolamine as a nitrogen source in the bovine intestinal content. Environmental Microbiology. 2011;13:365-377.
36. Parsons JP, Dinesh SD, Deery E, Leech HK, Brindley AA, Heldt D, Frank S, Smales CM, Lunsdorf H, Rambach A, Gass MH, Bleloch A, McClean KJ, Munro AW, Rigby SEJ, Warren MJ, Prentice MB. Biochemical and structural insights into bacterial organelle form and biogenesis. J Biol Chem. 2008;283:14366-14375.
37. Parsons JB, Frank S, Bhella D, Liang M, Prentice MB, Mulvihill DP, Warren MJ. Synthesis of Empty Bacterial Microcompartments, Directed Organelle Protein Incorporation, and Evidence of Filament-Associated Organelle Movement. Molecular Cell. 2010;38:305-315.
38. Fan C, Cheng S, Liu Y, Escobar CM, Crowley CS, Jefferson RE, Yeates TO, Bobik TA. Short N-terminal sequences package proteins into bacterial microcompartments. Proc Natl Acad Sci U S A. 2010;107:7509-14.
39. Lawrence AD, Frank S, Newnham S, Lee MJ, Brown IR, Xue W-F, Rowe ML, Mulvihill DP, Prentice MB, Howard MJ, Warren MJ. Solution structure of a bacterial microcompartment targeting peptide and its application in the construction of an ethanol bioreactor. ACS Synthetic Biology. 2014;3:454-465.
40. Martin W, Koonin EV. Introns and the origin of nucleus-cytosol compartmentalization. Nature. 2006;440:41-45.
41. Choudhary S, Quin MB, Sanders MA, Johnson ET, Schmidt-Dannert C. Engineered Protein Nano-Compartments for Targeted Enzyme Localization. PLoS ONE. 2012;7:e33342.
42. Schaffer DV, Koerber JT, Lim K-. Molecular Engineering of Viral Gene Delivery Vehicles. Annual Review of Biomedical Engineering. 2008;10:169-194.
43. Worsdorfer B, Woycechowsky KJ, Hilvert D. Directed evolution of a protein container. Science. 2011;331:589-592.
44. Neidhardt FC, Bloch PL, Smith DF. Culture Medium for Enterobacteria. J Bacteriol. 1974;119:736-747.
45. Sambrook J, Russell DW. Molecular Cloning: A Laboratory Manual. Woodbury NY: Cold Spring Harbor Laboratory Press; 2001
46. Sinha S, Cheng S, Fan C, Bobik TA. The PduM protein is a structural component of the microcompartments involved in coenzyme B₁₂-dependent 1,2-propanediol degradation by Salmonella. Journal of Bacteriology. 2012;194:1912-1918.
47. Sriramulu DD, Liang M, Hernandez-Romero D, Raux-Deery E, Lunsdorf H, Parsons JB, Warren MJ, Prentice MB. Lactobacillus reuteri DSM 20016 produces cobalamin-dependent diol dehydratase in metabolosomes and metabolises 1,2-propanediol by disproportionation. J Bacteriol. 2008;190:4559-4567.
48. Nahálka J, Gemeiner P, Bučko M, Wang PG. Bioenergy Beads: A Tool for Regeneration of ATP/NTP in Biocatalytic Synthesis. Artificial Cells, Blood Substitutes and Biotechnology. 2006;34:515-521.
49. Amado L, Kuzminov A. Polyphosphate Accumulation in Escherichia coli in Response to Defects in DNA Metabolism. J Bacteriol. 2009;191:7410-7416.
50. Ault-Riche D, Fraley CD, Tzeng C-M, Kornberg A. Novel Assay Reveals Multiple Pathways Regulating Stress-Induced Accumulations of Inorganic Polyphosphate in Escherichia coli. J Bacteriol. 1998;180:1841-1847.
51. Mullan A, Quinn JP, McGrath JW. A nonradioactive method for the assay of

- polyphosphate kinase activity and its application in the study of polyphosphate metabolism in *Burkholderia cepacia*. *Analytical Biochemistry*. 2002;308:294-299.
52. Kulakova AN, Hobbs D, Smithen M, Pavlov E, Gilbert JA, Quinn JP, McGrath JW. Direct Quantification of Inorganic Polyphosphate in Microbial Cells Using 4,Å≤-6-Diamidino-2-Phenylindole (DAPI). *Environmental Science & Technology*. 2011;45:7799-7803.
53. Eaton AD, Clesceri LS, Rice EW, Greenberg AE, Franson MAH, editors. *Standard Methods for the Examination of Water and Wastewater*. American Public Health Association; 2005
54. Serafim LS, Lemos PC, Levantesi C, Tandoi V, Santos H, Reis MAM. Methods for detection and visualization of intracellular polymers stored by polyphosphate-accumulating microorganisms. *Journal of Microbiological Methods*. 2002;51:1-18.
55. Spurr AR. A Low-Viscosity Epoxy Resin Embedding Medium for Electron Microscopy. *Journal of Ultrastructure Research*. 1969;26:31-43.
56. Lünsdorf H, Strömpl C, Osborn AM, Bennisar A, Moore ER, Abraham WR, Timmis KN. Approach to analyze interactions of microorganisms, hydrophobic substrates, and soil colloids leading to formation of composite biofilms, and to study initial events in microbiogeological processes. *Methods Enzymol*. 2001;336:317-331.
57. Bond PL, Keller J, Blackall LL. Anaerobic phosphate release from activated sludge with enhanced biological phosphorus removal. A possible mechanism of intracellular pH control. *Biotechnology and Bioengineering*. 1999;63:507-515.
58. Ahn K, Kornberg A. Polyphosphate kinase from *Escherichia coli*. Purification and demonstration of a phosphoenzyme intermediate. *J Biol Chem*. 1990;265:11734-11739.
59. Whitehead MP, Eagles L, Hooley P, Brown MRW. Most bacteria synthesize polyphosphate by unknown mechanisms. *Microbiology*. 2014;160:829-831.
60. Sharfstein ST, Keasling JD. Polyphosphate Metabolism in *Escherichia coli*. *Annals of the New York Academy of Sciences*. 1994;745:77-91.
61. Rao NN, Roberts MF, Torriani A. Amount and chain length of polyphosphates in *Escherichia coli* depend on cell growth conditions. *J Bacteriol*. 1985;162:242-247.
62. Van Dien SJ, Keyhani S, Yang C, Keasling JD. Manipulation of independent synthesis and degradation of polyphosphate in *Escherichia coli* for investigation of phosphate secretion from the cell. *Applied and Environmental Microbiology*. 1997;63:1689-1695.
63. Zhang X, Konarev PV, Petoukhov MV, Svergun DI, Xing L, Cheng RH, Haase I, Fischer M, Bacher A, Ladenstein R, Meining W. Multiple Assembly States of Lumazine Synthase: A Model Relating Catalytic Function and Molecular Assembly. *Journal of Molecular Biology*. 2006;362:753-770.
64. Seebeck FP, Woycechowsky KJ, Zhuang W, Rabe JP, Hilvert D. A Simple Tagging System for Protein Encapsulation. *Journal of the American Chemical Society*. 2006;128:4516-4517.
65. Laplagne DA, Zylberman V, Ainciart N, Steward MW, Sciutto E, Fossati CA, Goldbaum FA. Engineering of a polymeric bacterial protein as a scaffold for the multiple display of peptides. *Proteins: Structure, Function, and Bioinformatics*. 2004;57:820-828.

- 1 66. Wu W, Xing L, Zhou B, Lin Z. Active protein aggregates induced by terminally
2 attached self-assembling peptide ELK16 in Escherichia coli. *Microbial Cell*
3 *Factories*. 2011;10:9.
- 4 67. Nahalka J, Patoprsty V. Enzymatic synthesis of sialylation substrates powered by a
5 novel polyphosphate kinase (PPK3). *Organic & Biomolecular Chemistry*.
6 2009;7:1778-1780.
- 7 68. Herr A, Fischer R. Improvement of *Aspergillus nidulans* penicillin production by
8 targeting AcvA to peroxisomes. *Metab Eng*. 2014;25:131-139.
- 9 69. Johnson CL, Pechonick E, Park SD, Havemann GD, Leal NA, Bobik TA.
10 Functional genomic, biochemical, and genetic characterization of the *Salmonella*
11 *pduO* gene, an ATP:cob(I)alamin adenosyltransferase gene. *J Bacteriol*.
12 2001;183:1577-84.
- 13 70. Achbergerová L, Nahálka J. Polyphosphate - an ancient energy source and active
14 metabolic regulator. *Microbial Cell Factories*. 2011;10:63.
- 15

16 Acknowledgements

17 This research was supported by Health Research Board award HRA_POR/2011/111 to
18 MBP, and has emanated from research supported in part by a research grant from Science
19 Foundation Ireland (SFI) under Grant Number SFI/12/RC/2273. It was also supported by
20 grants from the British Biotechnology and Biological Sciences Research Council
21 (BBSRC), BB/M002969 and BB/H013180.

22

23

Table 1
Plasmids and strains used in this study

Plasmids and strains	Genotype*	Source
Plasmids		
pET23b	pBR322, T7 Ap	Novagen
pCOLADuet-1 TM	ColA ori lacI T7lac Kan ^r	Novagen
pET23b-GFPPduP18	pET23b with <i>gfp</i> [▲] and <i>pduP18</i> [†] leader sequence	Prof. Martin Warren, University of Kent
pLysSPduABJKNU (pSF37)	Cam ^R , Tet ^R <i>pduABJKNU</i> [†]	[37]
pML001	pET23b with pduP18 [†] - <i>ppk1</i> fusion without <i>gfp</i> [▲]	This study
pML002	pET23b- <i>ppk1</i>	This study
pCOLADuetPPK (pYY002)	pCOLADuet-1 with <i>ppk1</i>	This study
pCOLADuetP18PPK (pYY010)	pCOLADuet-1 with <i>pduP18</i> [†] - <i>ppk1</i> fusion	This study
pCOLADuetPPXPPK (pYY005)	pCOLADuet-1 with <i>ppk1</i> and <i>ppx</i>	This study
pCOLADuetP18PPKPPX (pYY007)	pCOLADuet-1 with <i>pduP18</i> [†] - <i>ppk1</i> fusion and <i>ppx</i>	This study
pCOLADuetD60PPXP18PPK (pYY008)	pCOLADuet-1 with <i>ppk1</i> and <i>pduD60</i> [†] - <i>ppx</i> fusion	This study
Strains		
<i>E.coli</i> JM109	<i>endA1 glnV44 thi-1 relA1 gyrA96 recA1 mcrB⁺ Δ(lac-proAB) e14- hsdR17(rK⁻ mK⁺)</i>	Promega
<i>E.coli</i> Top 10	<i>F⁻ mcrA Δ(mrr-hsdRMS-mcrBC) φ80lacZΔM15 ΔlacX74 nupG recA1 araD139 Δ(ara-leu)7697 galE15 galK16 rpsL(Str^R) endA1 λ⁻</i>	Invitrogen
<i>E.coli</i> BL21 (DE3)	<i>F⁻ ompT hsdS_B (r_B⁻ m_B) gal dcm</i> (DE3)	Stratagene
<i>E.coli</i> Tuner (DE3)	<i>F⁻ ompT hsdS_B (r_B⁻ m_B) gal dcm lacY1</i> (DE3)	Stratagene

*All inserts from *E.coli* JM109 unless specified [†]From *Citrobacter freundii* [▲]From *Aequorea victoria*

Figure Legends

Fig. 1. Effect of microcompartment-targeting of polyphosphate kinase (PPK1) in *E. coli*

- A. Proposed mechanism of increasing polyphosphate content of *E. coli* by microcompartment-targeting of polyphosphate kinase (PPK1).
- B. SDS-PAGE gel of *E. coli* BL21 (DE3) microcompartment extracts showing presence of PPK1 band. M: MW marker. NE: no enzyme, microcompartment only, (pLysSPduABJKNU). PPK1 : non-targeted PPK1 plus microcompartment, pML2 (ppk1) pLysSPduABJKNU. P18PPK1(2 lanes): microcompartment-targeted P18PPK1 fusion plus microcompartment, pML1 (p18ppk1) pLysSPduABJKNU.
- C & D. ATP generation assay with microcompartment fraction of *E. coli* BL21 (DE3) as substrate detecting polyphosphate kinase activity and polyphosphate when PPK1 is microcompartment-targeted. NE, PPK1, P18PPK1: as above. NS,P18PPK1: no shell, plasmid-located targeted PPK1 only, pML1 (p18ppk1). C: polyphosphate kinase (PPK1) assay with addition of ADP and polyphosphate. D: polyphosphate assay with addition of ADP alone.

Fig. 2. Co-expression of targeted PPK1 and recombinant microcompartments in *E. coli* results in stable polyphosphate retention and orthophosphate uptake. Dashed line with filled circles: NS, *E. coli* BL21 DE3 control. Continuous red line with filled squares : NS,P18PPK1, no shell, plasmid-located targeted PPK1 only, *E.coli* BL21 DE3 pML01 (p18ppk1). Continuous green line with filled triangles : S,P18PPK1, microcompartment-targeted P18PPK1 fusion plus microcompartment shell *E.coli* BL21 DE3 pML1 (p18ppk1) pLysSPduABJKNU

- A. Supernatant orthophosphate levels. B. Whole cell polyphosphate content

Fig. 3. Co-expression of microcompartment-targeted PPK1 and recombinant microcompartments in *E. coli* increases the polyphosphate content of the microcompartment fraction of lysed cells and protects it from co-expressed cytoplasmic polyphosphatase

DAPI polyphosphate assay from *E.coli* BL21 DE3 pLysSPduABJKNU all expressing recombinant microcompartments with different co-expressed enzymes. Blue bars polyphosphate content of microcompartment extractions, purple bars whole cell polyphosphate content. NE: no enzyme, microcompartment only, (pLysSPduABJKNU). S,PPK1 : non-targeted PPK1 and microcompartment, pML2 (ppk1). PPX,PPK1 : non-targeted PPK1 and non-targeted PPX, pYY005 (ppk1 ppx). D60PPX,P18PPK: targeted PPK1 and targeted PPX, pYY08 (ppk1 pduD60-ppx) . PPX,P18PPK1 : targeted PPK1 and non-targeted PPX, pYY07 (pduP18-ppk1 ppx). P18PPK1: targeted PPK1, pYY010 (pduP18-ppk1)

Fig. 4. Co-expression of targeted PPK1 and recombinant microcompartments in *E. coli* results in cytoplasmic polyphosphate granule formation persisting into stationary phase. Light microscopy of Neisser stained fixed cells (toluidine blue and chrysoidine counterstain. A,E,I: control *E. coli* BL21 DE3. B,F,J: *E. coli* BL21 DE3 NE: no enzyme, microcompartment only, (pLysSPduABJKNU). C,G,K *E.coli* BL21 DE3 pML01 (pduP18-ppk1). D,H,L BL21 DE3 pML01 (pduP18-ppk1) pLysSPduABJKNU. Incubation time in MOPS : A,B,C,D 4 hours, E,F,G,H 18 hours, I,J,K,L 44 hours.

Fig. 5. Phosphorus content of cytoplasmic granules in *E. coli* expressing recombinant polyphosphate kinase is confirmed by ultrastructural and electron-loss spectroscopic analysis using energy-filtered transmission electron microscopy (EFTEM) and is increased and qualitatively altered by recombinant microcompartment co-expression

A: control *E. coli* TunerTM(DE3). B: *E. coli* TunerTM (DE3) NE: no enzyme, microcompartment only, (pLysSPduABJKNU). C: *E. coli* BL21 DE3 pML01 (*pduP18-ppk1*). D,E,F,G: *E. coli* TunerTM (DE3) pET23bPduP18ppk1 pLySsPduABJKNU .

A-F: Electron spectroscopic imaging. Phosphorus signals are shown as overlays: green in A,B,C,F: red in D: yellow in E. Scale bar 1 μ m unless stated. G: Parallel electron energy-loss spectroscopy (PEELS) of the largest granule in E. The red line represents SpotPEELS of the large inclusion from E with the spot (size: 16 nm) placed centrally (electron micrograph inset). The green-boxed area represents the P-L2,3 energy-loss near-edge structure (ELNES), characterized by the two peaks (asterisks). The blue-coloured dashed spectrum is referenced from sodium polyphosphate.